Juno Therapeutics, Inc. Sustainability Profile
Juno Therapeutics, Inc., a prominent player in the biopharmaceutical industry, is headquartered in the United States, with significant operations across various regions. Founded in 2013, the company has rapidly established itself as a leader in the development of innovative cell therapies, particularly in the field of oncology. Juno is renowned for its pioneering work in CAR T-cell therapy, which harnesses the body’s immune system to target and eliminate cancer cells. This unique approach has led to groundbreaking treatments that have transformed patient outcomes in certain blood cancers. With a strong market position, Juno Therapeutics has achieved notable milestones, including successful clinical trials and partnerships that enhance its research capabilities. The company continues to push the boundaries of cancer treatment, striving to deliver life-changing therapies to patients worldwide.
DitchCarbon Score
How does Juno Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Juno Therapeutics, Inc.'s score of 20 is lower than 83% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Juno Therapeutics, Inc.'s reported carbon emissions
As of 2023, Juno Therapeutics, Inc., headquartered in the US, has not disclosed specific carbon emissions data, including Scope 1, 2, or 3 emissions. The company has not reported any significant reduction targets or initiatives related to carbon emissions. In previous years, Juno's energy consumption density was reported, with values of approximately 0.000323 in 2021, 0.000076 in 2022, and 0.000063 in 2023, all measured in RMB per unit of revenue. However, these figures do not provide a clear picture of their total emissions in kg CO2e. Currently, Juno Therapeutics does not appear to have cascaded emissions data from a parent or related organization, nor have they committed to any specific climate pledges or initiatives such as the Science Based Targets initiative (SBTi). The absence of detailed emissions data and reduction commitments highlights a potential area for improvement in their environmental strategy.
How Carbon Intensive is Juno Therapeutics, Inc.'s Industry?
How Carbon Intensive is Juno Therapeutics, Inc.'s Location?
Juno Therapeutics, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Juno Therapeutics, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
